{
    "clinical_study": {
        "@rank": "6442", 
        "arm_group": [
            {
                "arm_group_label": "Normal Hepatic Function (healthy volunteers)", 
                "arm_group_type": "Experimental", 
                "description": "Healthy volunteers with normal hepatic function will receive a single 33mg/kg dose of Ferriprox\u00ae."
            }, 
            {
                "arm_group_label": "Mild Hepatic Failure", 
                "arm_group_type": "Experimental", 
                "description": "Mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points will receive a single 33mg/kg dose of Ferriprox\u00ae."
            }, 
            {
                "arm_group_label": "Moderate Hepatic Failure", 
                "arm_group_type": "Experimental", 
                "description": "Moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points will receive a single 33 mg/kg dose of Ferriprox\u00ae."
            }
        ], 
        "brief_summary": {
            "textblock": "Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the\n      effect of impaired hepatic function on the PK of deferiprone and its 3-O-glucuronide\n      metabolite following a single oral dose of 33mg/kg Ferriprox\u00ae."
        }, 
        "brief_title": "An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hepatic Impairment", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Hepatic Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Post-marketing study to evaluate the effect of impaired hepatic function on the\n      pharmacokinetics (PK) of deferiprone and its 3-O-glucuronide metabolite and on the safety of\n      Ferriprox\u00ae in subjects with mild and moderate hepatic impairment as compared to healthy\n      volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n        All subjects:\n\n          1. Adult males or females, 18 - 75 years of age (inclusive);\n\n          2. Body weight \u2265 50 kg;\n\n          3. Body mass index (BMI) between 19 and 32 kg/mE2  (inclusive);\n\n          4. Absolute neutrophil count (ANC) of >1.5x10E9/L ;\n\n        Healthy volunteers:\n\n          1. Medically healthy with clinically insignificant screening results (e.g., laboratory\n             profiles, medical history, vital signs, physical examination);\n\n          2. Matched to hepatically impaired subjects in the study by age (+/- 10 years), sex and\n             weight (+/- 15% BMI).\n\n        Hepatically impaired subjects:\n\n          1. Considered clinically stable in the opinion of the Investigator;\n\n          2. Subjects with different degrees of impaired hepatic function as assessed by a\n             Child-Pugh classification score: mild (Class A: 5-6 points) and moderate (Class B:\n             7-9 points) impaired hepatic function.\n\n        Main Exclusion Criteria:\n\n          1. For subjects with hepatic impairment, fluctuating or rapidly deteriorating hepatic\n             function as indicated by clinical and/or laboratory signs of hepatic impairment (e.g.\n             advanced ascites, infection of ascites, fever, or active gastrointestinal bleeding).\n\n          2. Evidence of liver impairment in healthy volunteers: hepatitis B and C; or aspartate\n             aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, clotting factors,\n             serum protein that is considered clinically significant by the Investigator;\n\n          3. History or presence of significant clinically unstable respiratory, cardiovascular,\n             pulmonary, hepatic (except for subjects assigned to one of the hepatically impaired\n             groups), renal, hematologic, gastrointestinal, endocrine (except for subjects with\n             hepatic impairment with clinically stable and treated diabetes, hypertension and\n             thyroid disorders), immunologic, dermatologic, neurologic, or psychiatric disease;\n\n          4. Disorders or surgery of the gastrointestinal tract which may interfere with drug\n             absorption or may otherwise influence the PK of the investigational medicinal product\n             (e.g. resections of the small or large intestine, febrile conditions, chronic\n             diarrhea, chronic vomiting, clinically unstable endocrine disease, severe infections,\n             acute inflammations, etc.);\n\n          5. Received a pharmacological agent in another clinical trial within 28 days prior to\n             the first dose of the study;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767103", 
            "org_study_id": "LA40-0412"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normal Hepatic Function (healthy volunteers)", 
                "Mild Hepatic Failure", 
                "Moderate Hepatic Failure"
            ], 
            "intervention_name": "Ferriprox\u00ae", 
            "intervention_type": "Drug", 
            "other_name": [
                "DFP", 
                "Deferiprone", 
                "L1"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Deferiprone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatic Impairment", 
            "Liver Impairment", 
            "Liver Disease", 
            "Ferriprox\u00ae", 
            "LI", 
            "DFP", 
            "Deferiprone"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-Label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox\u00ae in Subjects With Impaired Hepatic Function and Healthy Volunteers", 
        "overall_official": {
            "affiliation": "ApoPharma", 
            "last_name": "Fernando Tricta, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic parameters will be assessed over a 24 hour interval using blood and urine samples for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal, mild and moderate hepatic impairment.", 
            "measure": "From serum and urine deferiprone concentration-time profiles: Cmax, Tmax, AUC0-t,AUC0-\u221e ,T\u00bd , CL/F,,CLr, Vd/F, Ae, Fe. From serum and urine deferiprone 3-O-glucuronide concentration-time profiles: Cmax, Tmax, AUC0-t, AUC0-\u221e, T\u00bd, CLr, Ae.", 
            "safety_issue": "No", 
            "time_frame": "Prior to dosing and at 0.25, 0.5, 0.75, 1, 1.333, 1.667, 2, 2.5, 3, 4, 6, 9, 12, 16 and 24 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767103"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety and tolerability will be assessed based on changes in: physical examinations, vital signs, 12-lead ECG, clinical laboratory tests, use of concomitant medication and frequency of  adverse events (AEs) following a single dose of Ferriprox.", 
            "measure": "Safety and tolerability of Ferriprox\u00ae in subjects with hepatic impairment.", 
            "safety_issue": "Yes", 
            "time_frame": "Prior to dosing until 48 hours post-dose."
        }, 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}